Infrastructure for National Genome Programmes
Governments worldwide are launching large-scale genomic initiatives — the UK’s 100,000 Genomes Programme, the US All of Us (1M+ participants), and Brazil’s Genomas Brasil (targeting 100,000 Brazilian genomes). These programmes share a common challenge: they need a scalable, compliant, interoperable data platform that can ingest, process, store, and analyse genomic data at population scale. Genomatis PopHealth is that platform — designed specifically for public health agencies, national programmes, and research biobanks.
Multi-Region Data Sovereignty
Deployed within the country’s borders or approved cloud regions. Full compliance with local data residency laws (GDPR, LGPD, HIPAA). Genomic data never leaves the jurisdiction unless explicitly authorised.
Population-Level Analytics
Aggregate variant frequency analysis, disease prevalence mapping, carrier frequency calculations, and ancestry-adjusted risk scoring across entire populations. Identify public health trends before they become crises.
Research Data Fabric
Federated data access layer enabling approved researchers to query de-identified genomic data without it leaving the secure environment. Supports cohort building, GWAS, and phenotype-genotype correlation studies.
Health Economics Reporting
Built-in HEOR dashboards demonstrating programme cost-effectiveness, diagnostic yield, clinical utility metrics, and return on investment — critical for securing continued government funding and public trust.
Scalable Data Lake
Apache Iceberg-based genomic data lake handling petabytes of VCF, BAM, and FASTQ files. Built for 100,000+ genomes with linear scalability to millions.
National Genome Programmes We Can Support and Add Relevant Outputs
Brazil — Genomas Brasil
36,000 genomes sequenced of 100,000 target. 250+ research projects across 19 states. Genomatis PopHealth provides the missing data integration and analysis layer.
Rare Disease Registries
Centralised variant databases for undiagnosed patients. Cross-referencing against global databases to end the diagnostic odyssey for the 300M people living with rare diseases.
Cancer Genomics Cohorts
Population-level tumour mutation profiling for national cancer strategies. Identify prevalent mutations, guide screening programmes, and inform treatment guidelines.
Pharmacogenomic Programmes
Nationwide PGx profiling to reduce adverse drug reactions. The WHO estimates ADRs account for 5–8% of hospital admissions globally — preventable with preemptive PGx.